Skip to main
AVBP

AVBP Stock Forecast & Price Target

AVBP Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 90%
Buy 10%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ArriVent BioPharma Inc. demonstrates a positive financial outlook due to the strong performance indicators of its lead product candidate, firmonertinib, which has shown enhanced mutant selectivity and improved potency against difficult-to-treat mutations in preclinical assays. The anticipated peak sales of approximately $1.2 billion, combined with favorable progression-free survival (PFS) outcomes that exceed those of widely used alternatives, position firmonertinib as a competitive and differentiated therapeutic option in the market. Furthermore, the commitment to developing next-generation antibody-drug conjugates, alongside advantages such as oral dosing and manageable safety profiles, supports a robust long-term growth trajectory for the company in addressing unmet medical needs in cancer treatment.

Bears say

ArriVent BioPharma's stock outlook appears negative due to several fundamental issues, including disappointing performance metrics for its lead product candidate, firmonertinib, which has shown underwhelming progression-free survival (PFS) results that could severely limit its adoption and commercial potential. Additionally, operational challenges such as trial enrollment delays and potential adverse safety signals may hinder the drug's market impact, further dampening investor confidence. The company's ambitious plans to innovate within a competitive landscape face significant scientific and execution risks, with expectations for any meaningful revenue contribution being pushed further into the next decade amidst unfavorable pricing dynamics and market entry barriers.

AVBP has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 90% of analysts recommend a Strong Buy, 10% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ArriVent Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ArriVent Biopharma Inc (AVBP) Forecast

Analysts have given AVBP a Strong Buy based on their latest research and market trends.

According to 10 analysts, AVBP has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ArriVent Biopharma Inc (AVBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.